PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31

PRECIGEN, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$6.66+0.28 (+4.31%)

Close on Oct 19, 2026

Market cap: $2.76B
P/E (TTM): –
Dividend yield: –

Dividends

Precigen has not reported a dividend

No dividend per share appears in Precigen's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in Precigen's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PGEN.

Revenue growth146.7% · median -63.3%

Operating margin-1141.1% · median -5947.9%

Net margin-1628.5% · median -3535.0%

Company	Revenue	Growth
PRLD	$22.42M	+220.3%
PGEN	$9.68M	+146.7%
ROIV	$7.53M	-67.6%
IMNM	$4.02M	-63.3%
PYXS	–	–
CBIO	–	–

Company

Next earnings (est.): Nov 12, 2026, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 20
Held by institutions: 39.2%
Auditor: Deloitte & Touche LLP
SEC CIK: 1356090

Advertisement
300 × 250